Onconetix, Inc. (ONCO)
0.4788
-0.07
(-12.63%)
USD |
NASDAQ |
Oct 16, 16:00
0.5301
+0.05
(+10.71%)
After-Hours: 20:00
Onconetix Enterprise Value : -3.937M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | -3.937M |
| October 15, 2026 | -3.674M |
| October 14, 2026 | -3.674M |
| October 13, 2026 | -3.648M |
| October 12, 2026 | -3.514M |
| October 09, 2026 | -3.401M |
| October 08, 2026 | -3.271M |
| October 07, 2026 | -3.488M |
| October 06, 2026 | -3.245M |
| October 05, 2026 | -3.200M |
| October 02, 2026 | -2.97M |
| October 01, 2026 | -2.930M |
| September 30, 2026 | -2.786M |
| September 29, 2026 | -2.643M |
| September 28, 2026 | -1.542M |
| September 25, 2026 | -1.846M |
| September 24, 2026 | -2.298M |
| September 23, 2026 | -2.301M |
| September 22, 2026 | -3.162M |
| September 21, 2026 | -3.269M |
| September 18, 2026 | -3.329M |
| September 17, 2026 | -3.236M |
| September 16, 2026 | -3.237M |
| September 15, 2026 | -3.306M |
| September 14, 2026 | -3.335M |
| Date | Value |
|---|---|
| September 11, 2026 | -2.884M |
| September 10, 2026 | -2.786M |
| September 09, 2026 | -2.668M |
| September 08, 2026 | -2.567M |
| September 04, 2026 | -1.884M |
| September 03, 2026 | -2.950M |
| September 02, 2026 | -3.195M |
| September 01, 2026 | -3.277M |
| August 31, 2026 | -3.376M |
| August 28, 2026 | -3.430M |
| August 27, 2026 | -3.356M |
| August 26, 2026 | -3.322M |
| August 25, 2026 | -3.314M |
| August 24, 2026 | -3.265M |
| August 21, 2026 | -3.286M |
| August 20, 2026 | -3.223M |
| August 19, 2026 | -3.056M |
| August 18, 2026 | -2.907M |
| August 17, 2026 | -2.880M |
| August 14, 2026 | -2.676M |
| August 13, 2026 | -2.406M |
| August 12, 2026 | -2.371M |
| August 11, 2026 | -2.080M |
| August 10, 2026 | -2.349M |
| August 07, 2026 | -2.371M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vistagen Therapeutics, Inc. | -22.07M |
| BridgeBio Pharma, Inc. | 15.66B |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.867M |
| Revenue (Quarterly) | 0.0171M |
| Total Expenses (Quarterly) | 2.884M |
| EPS Diluted (Quarterly) | -1.278 |
| Gross Profit Margin (Quarterly) | 25.15% |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -41.58K% |
| Normalized Earnings Yield | -53222.20 |